{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal ExoFlo",
            "NStudiesAvail": 430108,
            "NStudiesFound": 9,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 9,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Ventilator-free days at 28days",
                              "Change in partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio from pre-infusion baseline(Day 0)to Day 7.PaO2 may be calculated from arterial blood gas (ABG)or imputed from the SpO2daily."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "28 days",
                              "7 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05127122"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "\u2022 To evaluate the efficacy of intravenous ExoFlo in inducing clinical remission in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.",
                              "\u2022 To evaluate the efficacy of intravenous ExoFlo in inducing clinical response in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.",
                              "\u2022 To evaluate the efficacy of intravenous ExoFlo in improving disease-specific health-related quality of life.",
                              "\u2022 To evaluate the pharmacokinetics and pharmacodynamics of ExoFlo therapy, including changes in C-reactive protein (CRP), fecal calprotectin, fecal lactoferrin, and other pharmacodynamic biomarkers."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "\u2022 To evaluate the efficacy of intravenous ExoFlo in inducing clinical remission in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.",
                              "\u2022 To evaluate the efficacy of intravenous ExoFlo in inducing clinical response in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.",
                              "\u2022 To evaluate the efficacy of intravenous ExoFlo in improving disease-specific health-related quality of life.",
                              "\u2022 To evaluate the pharmacokinetics and pharmacodynamics of ExoFlo therapy, including changes in C-reactive protein (CRP), fecal calprotectin, fecal lactoferrin, and other pharmacodynamic biomarkers."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "70 weeks",
                              "70 weeks",
                              "70 weeks",
                              "70 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05130983"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change in viral load area under the curve (AUC) from baseline to Day=29",
                              "Proportion of patients showing symptom improvement or resolution Day=7, 11, 15",
                              "- Proportion of patients who required COVID-19 related hospitalization or Emergency Department Visit by Day 29"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in viral load area under the curve (AUC) from baseline to Day=29",
                              "Proportion of patients showing symptom improvement or resolution Day=7, 11, 15",
                              "- Proportion of patients who required COVID-19 related hospitalization or Emergency Department Visit by Day 29"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "61 days",
                              "61 days",
                              "61 Days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05125562"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of subjects with improvement with intravenous ExoFlo in inducing clinical remission in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
                              "Number of subjects with improvement with intravenous ExoFlo in inducing clinical response in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
                              "Number of subjects with improving disease-specific health-related quality of life after receiving intravenous ExoFlo.",
                              "Measurement of subject's C-reactive protein (CRP)",
                              "Measurement of subject fecal calprotectin",
                              "Measurement of subject fecal lactoferrin"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of subjects with improvement with intravenous ExoFlo in inducing clinical remission in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
                              "Number of subjects with improvement with intravenous ExoFlo in inducing clinical response in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
                              "Number of subjects with improving disease-specific health-related quality of life after receiving intravenous ExoFlo.",
                              "Measurement of subject's C-reactive protein (CRP)",
                              "Measurement of subject fecal calprotectin",
                              "Measurement of subject fecal lactoferrin"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "70 weeks",
                              "70 weeks",
                              "70 Weeks",
                              "70 Weeks",
                              "70 weeks",
                              "70 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05176366"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04657458"
                        ]
                  },
                  {
                        "Rank": 6,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Five dimensions include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression",
                              "Degree of breathlessness related to activity, graded 1-5."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "EuroQol-5D (EQ-5D)",
                              "Medical Research Council (MRC) Dyspnea Scale"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "61 days",
                              "61 Days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05116761"
                        ]
                  },
                  {
                        "Rank": 7,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05354141"
                        ]
                  },
                  {
                        "Rank": 8,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05215288"
                        ]
                  },
                  {
                        "Rank": 9,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The number of days from the first study treatment until return of oxygenation saturation (SpO2) \u2265 93% on room air (or PaO2/FiO2 \u2265 300 mmHg). If patient has chronic lung disease, recovery is defined as pre-COVID-19 SpO2 and O2 support.",
                              "Safety Endpoint",
                              "Efficacy Endpoint"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Time to Recovery",
                              "Incidence of Serious Adverse Events (SAE)",
                              "Number of Patients with All-cause Mortality"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "61 days",
                              "61 days",
                              "61 days"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Direct Biologics, LLC"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://directbiologics.com/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04493242"
                        ]
                  }
            ]
      }
}